James C C Wei

Suggest Changes
  • Citations Per Year
Learn More
OBJECTIVES Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3(More)
At various stages of my career, I made and followed plans for progress and growth. However, owing to several unexpected challenges, I had to make detours into unplanned vistas. When I look around at(More)
  • 1